Related Experiment Video
Updated: May 29, 2026

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
Published on: August 22, 2025
CRIP1a switches cannabinoid receptor agonist/antagonist-mediated protection from glutamate excitotoxicity
Brandon Stauffer1, Kathleen T Wallis, Steven P Wilson
1Department of Pharmacology and Toxicology, Medical College of Georgia, Georgia Health Sciences University, Augusta, GA 30912, USA.
Abstract:
A shared pathology among many neurological and neurodegenerative disorders is neuronal loss. Cannabinoids have been shown to be neuroprotective in multiple systems. However, both agonists and antagonists of the CB(1) cannabinoid receptor are neuroprotective, but the mechanisms responsible for these actions remain unclear. Recently a CB(1) receptor interacting protein, CRIP1a, was identified and found to alter CB(1) activity. Here we show that in an assay of glutamate neurotoxicity in primary neuronal cortical cultures CRIP1a disrupts agonist-induced neuroprotection and confers antagonist-induced neuroprotection.
Related Concept Videos
Antiepileptic Drugs: Glutamate Antagonists
Ligand-Gated Ion Channel Receptor: Gating Mechanism
GPCR Desensitization
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

